Chardan Capital Initiates Coverage On Intellia Therapeutics(NTLA). In a research note issued to the investors, the brokerage major Announces the price-target to $19 per share. The shares have been rated Buy. The rating by the stock financial advisor at Chardan Capital was issued on Mar 28, 2017 in a research report to their Investors and Clients.
Intellia Therapeutics (NTLA) shares turned negative on Fridays trading session with the shares closing down -0.12 points or -0.91% at a volume of 1,02,144. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $13.445. The peak price level was also seen at $13.445 while the days lowest was $12.93. Finally the shares closed at $13.07. The 52-week high of the shares is $30.4 while the 52-week low is $10.83. According to the latest information available, the market cap of the company is $471 M.
Intellia Therapeutics(NTLA) last announced its earnings results on Mar 14, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $5.627M. Analysts had an estimated revenue of $6.100M. Earnings per share were $-0.31. Analysts had estimated an EPS of $-0.23.